Sensorineural Hearing Loss Pipeline Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sensorineural Hearing Loss pipeline constitutes 15+ key companies continuously working towards developing 15+ Sensorineural Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Sensorineural Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Sensorineural Hearing Loss Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sensorineural Hearing Loss Market.

Some of the key takeaways from the Sensorineural Hearing Loss Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Sensorineural Hearing Loss treatment therapies with a considerable amount of success over the years.

*
Sensorineural Hearing Loss companies working in the treatment market are AudioCure Pharma GmbH, Frequency Therapeutics, Contineum Therapeutics, Otonomy, Inc., Frequency Therapeutics, Auris Medical AG, Sensorion, Nordmark Arzneimittel GmbH, Neuracle Science Co., Strekin AG, Autifony Therapeutics, Edison Pharmaceuticals, Albert Park, Regeneron Pharmaceuticals, ProQR Therapeutics, and others, are developing therapies for the Sensorineural Hearing Loss treatment

*
Emerging Sensorineural Hearing Loss therapies in the different phases of clinical trials are- AC102 gel, FX-322, PIPE-505, OTO-413, FX-322, AM-111, SENS-401, Ancrod, NS101, STR001-IT and STR001-ER, AUT00063, EPI-743, Valganciclovir, DB-OTO, Ultevursen, and others are expected to have a significant impact on the Sensorineural Hearing Loss market in the coming years.

*
In January 2023, Akouos, Inc., a subsidiary of Eli Lilly and Company, reported encouraging preliminary findings from the Phase 1/2 AK-OTOF-101 study. These results showed significant improvement in hearing within 30 days of AK-OTOF administration in the first participant, who had experienced profound hearing loss for over a decade. Further data, including initial observations from a second participant receiving AK-OTOF, will be shared during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

*
In January 2024, Sensorion, a biotechnology firm based in France, has announced approval to commence a Phase I/II clinical trial of its gene therapy, SENS-501, targeting gene-mediated hearing impairment in specific European regions. Named the Audiogene trial, this Phase I/II study is designed to assess the safety, tolerability, and efficacy of intra-cochlear administration of SENS-501. The trial aims to enroll two groups of pediatric patients, aged six to 31 months at the time of treatment. SENS-501 targets patients with mutations in the gene responsible for producing otoferlin protein, significantly increasing the risk of severe to profound sensorineural prelingual non-syndromic hearing loss.

Sensorineural Hearing Loss Overview

Sensorineural hearing loss (SNHL) is a type of hearing loss that occurs when there is damage to the inner ear (cochlea), the auditory nerve, or the pathways leading from the inner ear to the brain. It is one of the most common types of hearing loss and can range from mild to profound.

Get a Free Sample PDF Report to know more about Sensorineural Hearing Loss Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight [https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Sensorineural Hearing Loss Drugs Under Different Phases of Clinical Development Include:

*
AC102 gel: AudioCure Pharma GmbH

*
FX-322: Frequency Therapeutics

*
PIPE-505: Contineum Therapeutics

*
OTO-413: Otonomy, Inc.

*
FX-322: Frequency Therapeutics

*
AM-111: Auris Medical AG

*
SENS-401: Sensorion

*
Ancrod: Nordmark Arzneimittel GmbH

*
NS101: Neuracle Science Co.

*
STR001-IT and STR001-ER: Strekin AG

*
AUT00063: Autifony Therapeutics

*
EPI-743: Edison Pharmaceuticals

*
Valganciclovir: Albert Park

*
DB-OTO: Regeneron Pharmaceuticals

*
Ultevursen: ProQR Therapeutics

Sensorineural Hearing Loss Route of Administration

Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Sensorineural Hearing Loss Molecule Type

Sensorineural Hearing Loss Products have been categorized under various Molecule types, such as

*
Products have been categorized under various Molecule types such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Sensorineural Hearing Loss Pipeline Therapeutics Assessment

*
Sensorineural Hearing Loss Assessment by Product Type

*
Sensorineural Hearing Loss By Stage and Product Type

*
Sensorineural Hearing Loss Assessment by Route of Administration

*
Sensorineural Hearing Loss By Stage and Route of Administration

*
Sensorineural Hearing Loss Assessment by Molecule Type

*
Sensorineural Hearing Loss by Stage and Molecule Type

DelveInsight's Sensorineural Hearing Loss Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Sensorineural Hearing Loss product details are provided in the report. Download the Sensorineural Hearing Loss pipeline report to learn more about the emerging Sensorineural Hearing Loss therapies [https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Sensorineural Hearing Loss Therapeutics Market include:

Key companies developing therapies for Sensorineural Hearing Loss are - Austar Hearing Science and Technology, Lively Hearing Corporation, Audifon, Foshan Vohom Technology, ZOUNDS Hearing, SeboTek Hearing Systems, Arphi Electronics, Audina Hearing Instruments, Elkon, WS Audiology, Eargo, Horente, IN4 Technology Corporation, Nano Hearing Aids, LORECa, Earlens Corporation, Sonova Group, Demant, GN Store Nord A/S, Cochlear Ltd., RION Co., Ltd., Starkey, Nurotron Biotechnology, MED-EL, and others.

Sensorineural Hearing Loss Pipeline Analysis:

The Sensorineural Hearing Loss pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Sensorineural Hearing Loss with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sensorineural Hearing Loss Treatment.

*
Sensorineural Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Sensorineural Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sensorineural Hearing Loss market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sensorineural Hearing Loss drugs and therapies [https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sensorineural Hearing Loss Pipeline Market Drivers

*
Rise in the Incidence of Sensorineural hearing loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Sensorineural Hearing Loss Market.

Sensorineural Hearing Loss Pipeline Market Barriers

*
However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Sensorineural Hearing Loss Market growth.

Scope of Sensorineural Hearing Loss Pipeline Drug Insight

*
Coverage: Global

*
Key Sensorineural Hearing Loss Companies: AudioCure Pharma GmbH, Frequency Therapeutics, Contineum Therapeutics, Otonomy, Inc., Frequency Therapeutics, Auris Medical AG, Sensorion, Nordmark Arzneimittel GmbH, Neuracle Science Co., Strekin AG, Autifony Therapeutics, Edison Pharmaceuticals, Albert Park, Regeneron Pharmaceuticals, ProQR Therapeutics, and others

*
Key Sensorineural Hearing Loss Therapies: AC102 gel, FX-322, PIPE-505, OTO-413, FX-322, AM-111, SENS-401, Ancrod, NS101, STR001-IT and STR001-ER, AUT00063, EPI-743, Valganciclovir, DB-OTO, Ultevursen, and others

*
Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies

*
Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers

Request for Sample PDF Report for Sensorineural Hearing Loss Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Sensorineural Hearing Loss Report Introduction

2. Sensorineural Hearing Loss Executive Summary

3. Sensorineural Hearing Loss Overview

4. Sensorineural Hearing Loss- Analytical Perspective In-depth Commercial Assessment

5. Sensorineural Hearing Loss Pipeline Therapeutics

6. Sensorineural Hearing Loss Late Stage Products (Phase II/III)

7. Sensorineural Hearing Loss Mid Stage Products (Phase II)

8. Sensorineural Hearing Loss Early Stage Products (Phase I)

9. Sensorineural Hearing Loss Preclinical Stage Products

10. Sensorineural Hearing Loss Therapeutics Assessment

11. Sensorineural Hearing Loss Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sensorineural Hearing Loss Key Companies

14. Sensorineural Hearing Loss Key Products

15. Sensorineural Hearing Loss Unmet Needs

16 . Sensorineural Hearing Loss Market Drivers and Barriers

17. Sensorineural Hearing Loss Future Perspectives and Conclusion

18. Sensorineural Hearing Loss Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sensorineural-hearing-loss-pipeline-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-sensorion-fennec-pharma-sound-pharma-decibel-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.